Bills · S 2697
IN COMMITTEE· 119TH CONGRESS
Senate BillS 2697Health
National Biotechnology Safety Act
INTRO SEP 3· LAST ACTION SEP 3
READING
7MIN
COSPONSORS
1
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed Senate
Passed House
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenVoters should care about this bill because biotechnology is rapidly advancing, bringing both exciting innovations and potential concerns. This bill directly addresses the need for better scientific understanding of the safety of these new technologies, which can affect our food supply, health, and environment. If this bill becomes law, it could lead to more informed and transparent government regulation of biotechnology, potentially preventing unforeseen problems while also streamlining the process for beneficial products to reach the market safely.
Without this legislation, research into biotechnology safety might be less coordinated or funded, potentially leaving gaps in our knowledge. This could result in either overly cautious regulations that stifle innovation or, conversely, inadequate oversight that allows unsafe products to reach the public. By investing in dedicated risk assessment research, the bill aims to strike a better balance, ensuring that both innovation and public safety are prioritized as biotechnology continues to evolve and integrate into various aspects of daily life.
KEY PROVISIONS
5AI-extractedPROVISION 01
Establishes a biotechnology risk assessment research program within the National Science Foundation (NSF).
This creates a dedicated funding stream and focus for scientific research into the safety of biotechnology.
PROVISION 02
Prioritizes research on identifying unintended effects, developing risk management practices, and monitoring the environmental impact of biotech organisms.
This ensures the funded research directly addresses the most critical safety questions and concerns related to new biotechnologies.
PROVISION 03
Requires the NSF to consult with federal regulatory agencies (USDA, FDA, EPA) on research applicability and regulatory assistance.
This ensures the research findings are directly relevant and useful for federal agencies responsible for regulating biotechnology products.
PROVISION 04
Authorizes $50,000,000 annually for fiscal years 2026 through 2030 for the NSF program.
This provides substantial, dedicated funding necessary to conduct meaningful and long-term research into biotechnology safety.
PROVISION 05
Directs the National Academies of Science, Engineering, and Medicine to conduct a two-phase study on biotechnology safety and benefits.
This provides an independent, expert assessment of biotechnology risks and benefits, offering recommendations for regulatory frameworks.
SPONSORSHIP
1 + 1
R· Indiana
YRS IN OFFICE
15
BILLS LED
65
COSPONSOR BREAKDOWNBIPARTISAN · 0%
DEM 1 REP 0 IND 0
ACTION TIMELINE
2 EVENTSSEP 3
Introduced in Senate
SEP 3
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
BILL INFO
TypeSenate Bill
NumberS 2697
Congress119th
StatusIn Committee
IntroducedSep 3, 2025
Last actionSep 3, 2025
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · HEALTH, EDUCATION, LABOR, AND PENSIONS COMMITTEE · INTRODUCED SEP 3, 2025
Senate BillS 2697Health
National Biotechnology Safety Act
INTRODUCED SEP 3, 2025· LAST ACTION SEP 3, 2025
PASSAGE CHANCES
—%
READING
7 min
COSPONSORS
1
COMPLEXITY
Moderate
